Abstract

Through the studies of patients with hypophosphatemic rickets/osteomalacia, FGF23 has emerged as a humoral factor that reduces serum phosphate. Discovery of FGF23 as an essential regulator of phosphate homeostasis has markedly improved our understanding of phosphate homeostasis and hypophosphatemic or hyperphosphatemic disorders. Measurement of circulatory FGF23 levels seems to be useful for diagnosis of these disorder. Novel therapeutic methods for these disorder may be developed by elucidation of the mechanism of action of FGF23.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call